Skip Navigation


American Journal of Epidemiology Advance Access originally published online on October 29, 2008
American Journal of Epidemiology 2008 168(12):1343-1352; doi:10.1093/aje/kwn259
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrowOA All Versions of this Article:
168/12/1343    most recent
kwn259v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Basta, N. E.
Right arrow Articles by Longini, I. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Basta, N. E.
Right arrow Articles by Longini, I. M., Jr.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

American Journal of Epidemiology © 2008 The Authors
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Estimating Influenza Vaccine Efficacy From Challenge and Community-based Study Data

Nicole E. Basta, M. Elizabeth Halloran, Laura Matrajt and Ira M. Longini, Jr.

Correspondence to Dr. Ira M. Longini, Jr., Program in Biostatistics and Biomathematics, Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, Seattle, WA 98109 (e-mail: longini{at}scharp.org).

Received for publication April 24, 2008. Accepted for publication July 28, 2008.

In this paper, the authors provide estimates of 4 measures of vaccine efficacy for live, attenuated and inactivated influenza vaccine based on secondary analysis of 5 experimental influenza challenge studies in seronegative adults and community-based vaccine trials. The 4 vaccine efficacy measures are for susceptibility (VES), symptomatic illness given infection (VEP), infection and illness (VESP), and infectiousness (VEI). The authors also propose a combined (VEC) measure of the reduction in transmission in the entire population based on all of the above efficacy measures. Live influenza vaccine and inactivated vaccine provided similar protection against laboratory-confirmed infection (for live vaccine: VES = 41%, 95% confidence interval (CI): 15, 66; for inactivated vaccine: VES = 43%, 95% CI: 8, 79). Live vaccine had a higher efficacy for illness given infection (VEP = 67%, 95% CI: 24, 100) than inactivated vaccine (VEP = 29%, 95% CI: –19, 76), although the difference was not statistically significant. VESP for the live vaccine was higher than for the inactivated vaccine. VEI estimates were particularly low for these influenza vaccines. VESP and VEC can remain high for both vaccines, even when VEI is relatively low, as long as the other 2 measures of vaccine efficacy are relatively high.

communicable disease control; immunization; influenza, human; influenza vaccines; models, theoretical; research design

Abbreviations: AR, attack rate; CI, confidence interval; RR, relative risk; VE, vaccine efficacy; VEC, combined vaccine efficacy; VEI, vaccine efficacy for infectiousness; VEP, vaccine efficacy for illness given infection; VES, vaccine efficacy for susceptibility; VESP, vaccine efficacy for infection-confirmed influenza illness


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.